Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 28, 2025
Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa
Leyla Larsson, Claire J Calderwood, Edson T Marambire, et al.
The Journal of Antimicrobial Chemotherapy
|
March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043
Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Frontiers in Antibiotics
|
June 6, 2025
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 18, 2015
A Step toward an Optimized Rifampin Dose Completed
Martin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
Frontiers in Immunology
|
October 17, 2018
Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy
Mohamed I M Ahmed, Nyanda E Ntinginya, Gibson Kibiki, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis
Martin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
Elin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Nature Communications
|
January 18, 2025
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis
Andreas Römpp, Axel Treu, Julia Kokesch-Himmelreich, et al.
The Pediatric Infectious Disease Journal
|
February 28, 2023
Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease: A Diagnostic Accuracy Study for Pediatric Tuberculosis
Laura Olbrich, Marriott Nliwasa, Issa Sabi, et al.
The Lancet. Microbe
|
January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Norbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 28, 2025
Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa
Leyla Larsson, Claire J Calderwood, Edson T Marambire, et al.
The Journal of Antimicrobial Chemotherapy
|
March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043
Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Frontiers in Antibiotics
|
June 6, 2025
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 18, 2015
A Step toward an Optimized Rifampin Dose Completed
Martin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
Frontiers in Immunology
|
October 17, 2018
Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy
Mohamed I M Ahmed, Nyanda E Ntinginya, Gibson Kibiki, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis
Martin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
Elin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Nature Communications
|
January 18, 2025
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis
Andreas Römpp, Axel Treu, Julia Kokesch-Himmelreich, et al.
The Pediatric Infectious Disease Journal
|
February 28, 2023
Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease: A Diagnostic Accuracy Study for Pediatric Tuberculosis
Laura Olbrich, Marriott Nliwasa, Issa Sabi, et al.
The Lancet. Microbe
|
January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Norbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
Page
of 9